$10.38
0.95%
Nasdaq, Mar 28, 09:00 pm CET
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Roivant Sciences Stock price

$10.38
-0.36 3.35% 1M
-1.16 10.05% 6M
-1.45 12.26% YTD
-0.16 1.52% 1Y
+5.60 117.15% 3Y
+1.03 11.02% 5Y
+1.03 11.02% 10Y
Nasdaq, Closing price Fri, Mar 28 2025
-0.10 0.95%
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Key metrics

Market capitalization $7.41b
Enterprise Value $2.70b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 27.71
P/S ratio (TTM) P/S ratio 75.92
P/B ratio (TTM) P/B ratio 1.44
Revenue growth (TTM) Revenue growth -20.84%
Revenue (TTM) Revenue $97.56m
EBIT (operating result TTM) EBIT $-1.11b
Free Cash Flow (TTM) Free Cash Flow $-779.48m
Cash position $5.15b
EPS (TTM) EPS $-0.14
P/E forward negative
P/S forward 52.39
EV/Sales forward 19.12
Short interest 9.79%
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Roivant Sciences forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Roivant Sciences forecast:

Buy
90%
Hold
10%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
98 98
21% 21%
100%
- Direct Costs 16 16
52% 52%
17%
93 93
4% 4%
96%
- Selling and Administrative Expenses 656 656
10% 10%
673%
- Research and Development Expense 538 538
5% 5%
551%
-1,102 -1,102
8% 8%
-1,129%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -1,113 -1,113
6% 6%
-1,140%
Net Profit -117 -117
103% 103%
-120%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Positive
Investors Business Daily
12 days ago
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
Neutral
GlobeNewsWire
12 days ago
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
Neutral
GlobeNewsWire
13 days ago
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 908
Founded 2014
Website www.roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today